Scabies in infants and children - a narrative review.
Anca E ChiriacAdriana DiaconeasaRaluca MiulescuAnca E ChiriacUwe WollinaPublished in: European journal of pediatrics (2024)
Scabies is a human ectoparasitosis caused by Sarcoptes scabei var. hominis. World-wide around 300 million patients are affected. Infants and children have the highest incidence rates. Poverty and overcrowding are social factors contributing to a higher risk of transmission and treatment failure. The leading symptom of the infestation is itch. Complications are bacterial infections that are responsible for mortality. Diagnosis is clinical. Non-invasive imaging technologies like dermoscopy can be used. Polymerase chain reaction (PCR) is less sensitive and specific than microscopy of skin scrapings. Treatment of choice is topical permethrin 5%. Ivermectin is the only oral drug FDA-approved for scabies. It should be used in cases non-responsive to topical therapy and in case of high number of infested patients in addition to topical therapy. Pseudo-resistance to treatment is not uncommon. New drugs are on the horizon. What is Known: • Pruritus is the leading symptom causing sleep disturbances and scratching with the risk of secondary bacterial infections. • Treatment failure is related to inappropriate application of topical drugs and asymptomatic family members. What is New: • COVID-19 pandemic and migration are contributing to an increased incidence of scabies. • New compounds to treat scabies are on the horizon.
Keyphrases
- newly diagnosed
- high resolution
- ejection fraction
- young adults
- healthcare
- cardiovascular disease
- endothelial cells
- wound healing
- stem cells
- mental health
- mass spectrometry
- type diabetes
- depressive symptoms
- cardiovascular events
- combination therapy
- drug delivery
- single molecule
- single cell
- replacement therapy
- fluorescence imaging